Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial

Laryngoscope

Volumn 127, Issue 8, 2017, Pages 1808-1815

  Curry, Joseph ^a   Johnson, Jennifer ^a   Tassone, Patrick ^a   Vidal, Marina Domingo ^a   Menezes, Diana Whitaker ^a   Sprandio, John ^a   Mollaee, Mehri ^a   Cotzia, Paolo ^a   Birbe, Ruth ^a   Lin, Zhao ^a   Gill, Kurren ^a   Duddy, Elizabeth ^a   Zhan, Tingting ^b   Leiby, Benjamin ^b   Reyzer, Michelle ^c   Cognetti, David ^a   Luginbuhl, Adam ^a   Tuluc, Madalina ^a   Martinez Outschoorn, Ubaldo ^a  

^a Department of Otolaryngology–Head and Neck Surgery ^*  (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Head and neck cancer; metformin; squamous cell carcinoma; tumor metabolism

Indexed keywords

ALANINE AMINOTRANSFERASE; BETA GALACTOSIDASE; CAVEOLIN 1; GLUCOSE; KI 67 ANTIGEN; LACTIC ACID; METFORMIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; CANCER SURGERY; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFECT; FATIGUE; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEAD AND NECK SURGERY; HEMORRHOID; HUMAN; HUMAN TISSUE; HYPOPHARYNX SQUAMOUS CELL CARCINOMA; IMMUNOHISTOCHEMISTRY; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; LARYNX SQUAMOUS CELL CARCINOMA; MALE; MASS SPECTROMETRY; MOUTH SQUAMOUS CELL CARCINOMA; NAUSEA; OROPHARYNX SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; SIDE EFFECT; SQUAMOUS CELL SKIN CARCINOMA; TUMOR BIOPSY; TUMOR MICROENVIRONMENT; TUNEL ASSAY; WEAKNESS; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; HEAD AND NECK NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; METFORMIN; MIDDLE AGED; TUMOR MICROENVIRONMENT;

EID: 85012965281     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1002/lary.26489     Document Type: Article

References (73)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7–30.
2. Kawecki A, Krajewski R. Follow-up in patients treated for head and neck cancer. Memo 2014;7:87–91.
3. Bann DV, Deschler DG, Goyal N. Novel immunotherapeutic approaches for head and neck squamous cell carcinoma. Cancers (Basel) 2016;8. pii: E87.
4. Skinner HD, McCurdy MR, Echeverria AE, et al. Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol 2013;52:1002–1009.
5. Sandulache VC, Hamblin JS, Skinner HD, Kubik MW, Myers JN, Zevallos JP. Association between metformin use and improved survival in patients with laryngeal squamous cell carcinoma. Head Neck 2014;36:1039–1043.
6. Yen YC, Lin C, Lin SW, Lin YS, Weng SF. Effect of metformin on the incidence of head and neck cancer in diabetics. Head Neck 2015;37:1268–1273.
7. Rego DF, Pavan LM, Elias ST, De Luca Canto G, Guerra EN. Effects of metformin on head and neck cancer: a systematic review. Oral Oncol 2015;51:416–422.
8. Pollak M. Overcoming drug development bottlenecks with repurposing: repurposing biguanides to target energy metabolism for cancer treatment. Nat Med 2014;20:591–593.
9. Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: from mechanisms of action to therapies. Cell Metab 2014;20:953–966.
10. Martinez-Outschoorn UE, Peiris-Pagés M, Pestell RG, Sotgia F, Lisanti MP. Nat Rev Clin Oncol. 2017;14:11–31. doi:10.1038/nrclinonc.2016.60. Review. PMID: 27141887
11. El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 2000;275:223–228.
12. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 2000;348:607–614.
13. Wheaton WW, Weinberg SE, Hamanaka RB, et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. Elife 2014;3:e02242.
14. Chandel NS, Avizonis D, Reczek CR, et al. Are Metformin doses used in murine cancer models clinically relevant? Cell Metab 2016;23:569–570.
15. Andrzejewski S, Gravel SP, Pollak M, St-Pierre J. Metformin directly acts on mitochondria to alter cellular bioenergetics. Cancer Metab 2014;2:12.
16. Madiraju AK, Erion DM, Rahimi Y, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 2014;510:542–546.
17. Luo Q, Hu D, Hu S, Yan M, Sun Z, Chen F. In vitro and in vivo anti-tumor effect of metformin as a novel therapeutic agent in human oral squamous cell carcinoma. BMC Cancer 2012;12:517.
18. Harada K, Ferdous T, Harada T, Ueyama Y. Metformin in combination with 5-fluorouracil suppresses tumor growth by inhibiting the Warburg effect in human oral squamous cell carcinoma. Int J Oncol 2016;49:276–284.
19. Ueno S, Kimura T, Yamaga T, et al. Metformin enhances anti-tumor effect of L-type amino acid transporter 1 (LAT1) inhibitor. J Pharmacol Sci 2016;131:110–117.
20. Martinez-Outschoorn UE, Lisanti MP, Sotgia F. Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth. Semin Cancer Biol 2014;25:47–60.
21. Romero IL, Mukherjee A, Kenny HA, Litchfield LM, Lengyel E. Molecular pathways: trafficking of metabolic resources in the tumor microenvironment. Clin Cancer Res 2015;21:680–686.
22. DeNicola GM, Cantley LC. Cancer's fuel choice: new flavors for a picky eater. Mol Cell 2015;60:514–523.
23. Schulze A, Harris AL. How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature 2012;491:364–373.
24. Martinez-Outschoorn UE, Sotgia F, Lisanti MP. Power surge: supporting cells “fuel” cancer cell mitochondria. Cell Metab 2012;15:4–5.
25. Wallace DC. Mitochondria and cancer. Nat Rev Cancer 2012;12:685–698.
26. Marchiq I, Pouyssegur J. Hypoxia, cancer metabolism and the therapeutic benefit of targeting lactate/H symporters. J Mol Med (Berl) 2016;94:155–171.
27. Curry JM, Tuluc M, Whitaker-Menezes D, et al. Cancer metabolism, stemness and tumor recurrence: MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer. Cell Cycle 2013;12:1371–1384.
28. Jensen DH, Therkildsen MH, Dabelsteen E. A reverse Warburg metabolism in oral squamous cell carcinoma is not dependent upon myofibroblasts. J Oral Pathol Med 2015;44:714–721.
29. Curry JM, Sprandio J, Cognetti D, et al. Tumor microenvironment in head and neck squamous cell carcinoma. Semin Oncol 2014;41:217–234.
30. Martinez-Outschoorn UE, Sotgia F, Lisanti MP. Caveolae and signalling in cancer. Nat Rev Cancer 2015;15:225–237.
31. Pavlides S, Whitaker-Menezes D, Castello-Cros R, et al. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 2009;8:3984–4001.
32. Asterholm IW, Mundy DI, Weng J, Anderson RG, Scherer PE. Altered mitochondrial function and metabolic inflexibility associated with loss of caveolin-1. Cell Metab 2012;15:171–185.
33. Schwamborn K, Caprioli RM. Molecular imaging by mass spectrometry—looking beyond classical histology. Nat Rev Cancer 2010;10:639–646.
34. Van de Plas R, Yang J, Spraggins J, Caprioli RM. Image fusion of mass spectrometry and microscopy: a multimodality paradigm for molecular tissue mapping. Nat Methods 2015;12:366–372.
35. Taverna D, Pollins AC, Sindona G, Caprioli RM, Nanney LB. Imaging mass spectrometry for accessing molecular changes during burn wound healing. Wound Repair Regen 2016;24:775–785.
36. Strohalm M, Hassman M, Kosata B, Kodicek M. mMass data miner: an open source alternative for mass spectrometric data analysis. Rapid Commun Mass Spectrom 2008;22:905–908.
37. Niraula S, Dowling RJ, Ennis M, et al. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat 2012;135:821–830.
38. Hosono K, Endo H, Takahashi H, et al. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila) 2010;3:1077–1083.
39. Cazzaniga M, DeCensi A, Pruneri G, et al. The effect of metformin on apoptosis in a breast cancer presurgical trial. Br J Cancer 2013;109:2792–2797.
40. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646–674.
41. Sikka A, Kaur M, Agarwal C, Deep G, Agarwal R. Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation. Cell Cycle 2012;11:1374–1382.
42. Skinner HD, Sandulache VC, Ow TJ, et al. TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res 2012;18:290–300.
43. Vitale-Cross L, Molinolo AA, Martin D, et al. Metformin prevents the development of oral squamous cell carcinomas from carcinogen-induced premalignant lesions. Cancer Prev Res (Phila) 2012;5:562–573.
44. Woo SH, Sandulache VC, Yang L, Skinner HD. Evaluating response to metformin/cisplatin combination in cancer cells via metabolic measurement and clonogenic survival. Methods Mol Biol 2014;1165:11–18.
45. Ben Sahra I, Laurent K, Giuliano S, et al. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res 2010;70:2465–2475.
46. Tomic T, Botton T, Cerezo M, et al. Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell Death Dis 2011;2:e199.
47. Pollak M. Potential applications for biguanides in oncology. J Clin Invest 2013;123:3693–3700.
48. Gronroos TJ, Lehtio K, Soderstrom KO, et al. Hypoxia, blood flow and metabolism in squamous-cell carcinoma of the head and neck: correlations between multiple immunohistochemical parameters and PET. BMC Cancer 2014;14:876.
49. Javeshghani S, Zakikhani M, Austin S, et al. Carbon source and myc expression influence the antiproliferative actions of metformin. Cancer Res 2012;72:6257–6267.
50. Birsoy K, Possemato R, Lorbeer FK, et al. Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature 2014;508:108–112.
51. Labi V, Erlacher M. How cell death shapes cancer. Cell Death Dis 2015;6:e1675.
52. Sotgia F, Martinez-Outschoorn UE, Howell A, Pestell RG, Pavlides S, Lisanti MP. Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. Annu Rev Pathol 2012;7:423–467.
53. Harris AL. Metabolic compartments in tumor tissue: implications for therapy. Cell Cycle 2012;11:13–14.
54. Martinez-Outschoorn UE, Pavlides S, Whitaker-Menezes D, et al. Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: implications for breast cancer and DCIS therapy with autophagy inhibitors. Cell Cycle 2010;9:2423–2433.
55. Bartholomew JN, Volonte D, Galbiati F. Caveolin-1 regulates the antagonistic pleiotropic properties of cellular senescence through a novel Mdm2/p53-mediated pathway. Cancer Res 2009;69:2878–2886.
56. Campisi J. Aging, cellular senescence, and cancer. Annu Rev Physiol 2013;75:685–705.
57. Dimri GP, Lee X, Basile G, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995;92:9363–9367.
58. Kim YM, Seo YH, Park CB, Yoon SH, Yoon G. Roles of GSK3 in metabolic shift toward abnormal anabolism in cell senescence. Ann N Y Acad Sci 2010;1201:65–71.
59. Ros S, Schulze A. Linking glycogen and senescence in cancer cells. Cell Metab 2012;16:687–688.
60. Favaro E, Bensaad K, Chong MG, et al. Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells. Cell Metab 2012;16:751–764.
61. Kaplon J, Zheng L, Meissl K, et al. A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature 2013;498:109–112.
62. Li M, Durbin KR, Sweet SM, Tipton JD, Zheng Y, Kelleher NL. Oncogene-induced cellular senescence elicits an anti-Warburg effect. Proteomics 2013;13:2585–2596.
63. Salmenpera P, Karhemo PR, Rasanen K, Laakkonen P, Vaheri A. Fibroblast spheroids as a model to study sustained fibroblast quiescence and their crosstalk with tumor cells. Exp Cell Res 2016;345:17–24.
64. Bovenzi CD, Hamilton J, Tassone P, et al. Prognostic indications of elevated MCT4 and CD147 across cancer types: a meta-analysis. Biomed Res Int 2015;2015:242437.
65. Hadad S, Iwamoto T, Jordan L, et al. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat 2011;128:783–794.
66. Dowling RJ, Lam S, Bassi C, et al. Metformin pharmacokinetics in mouse tumors: implications for human therapy. Cell Metab 2016;23:567–568.
67. Sandulache VC, Skinner HD, Ow TJ, et al. Individualizing antimetabolic treatment strategies for head and neck squamous cell carcinoma based on TP53 mutational status. Cancer 2012;118:711–721.
68. Jinhua X, Ji W, Shouliang C, et al. Expression of immune checkpoints in T cells of esophageal cancer patients. Oncotarget 2016;7:63669–63678. doi: 10.18632/oncotarget.11611.
69. Quan H, Fang L, Pan H, et al. An adaptive immune response driven by mature, antigen-experienced T and B cells within the microenvironment of oral squamous cell carcinoma. Int J Cancer 2016;138:2952–2962.
70. Economopoulou P, Kotsantis I, Psyrri A. Checkpoint inhibitors in head and neck cancer: rationale, clinical activity, and potential biomarkers. Curr Treat Options Oncol 2016;17:40.
71. Eikawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E, Udono H. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci U S A 2015;112:1809–1814.
72. Tian Y, Tang B, Wang C, et al. Metformin mediates resensitivity to 5-fluorouracil in hepatocellular carcinoma via the suppression of YAP. Oncotarget 2016;7:46230–46241.
73. Peng M, Huang Y, Tao T, et al. Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk. Sci Rep 2016;6:28611.